Arch Iran Med. 2020;23(12): 835-841.
doi: 10.34172/aim.2020.111

Scopus ID: 85097789596
  Abstract View: 1405
  PDF Download: 685

Original Article

Hepatitis B Virus Screening and Real Life Data in Patients with Solid Tumor Receiving Chemotherapy

Sami Fidan 1 ORCID logo, Evren Fidan 2* ORCID logo, Celal Alandağ 2, Murat Erkut 1, Arif Mansur Cosar 1

1 Department of Gastroenterology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
2 Department of Medical Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
*Corresponding Author: *Corresponding Author: Evren Fidan, MD; Karadeniz Technical University, Faculty of Medicine, Division of Medical Oncology, Trabzon, 61080, Turkey. Tel: +90- 462-3775550; Fax: +90-462-3252270; Email: , Email: evrenkarafidan@yahoo.com


Background: Reactivation of the hepatitis B virus (HBV) either during or after chemotherapy may cause serious and sometimes fatal hepatitis. All patients undergoing chemotherapy should therefore be screened in terms of HBV before chemotherapy. The purpose of this research was to identify HBV screening rates in patients with solid cancer undergoing parenteral chemotherapy and to determine the outcomes of patients undergoing HBV screening.

Methods: Data for patients undergoing parenteral chemotherapy for solid cancer from January 1, 2012 to December 30, 2018 were retrieved from our electronic health record patient files in this retrospective study. Screening was defined as hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) tests carried out within six months prior the first chemotherapy session.

Results: Four thousand fifty-eight (63%) of the 6440 patients who underwent parenteral chemotherapy were screened for HBsAg and/or HBcAb. The proportions of patients screened for HBsAg and HBcAb improved from 38.8% (2012) to 76.3% (2018), and from 0.2% (2012) to 43% (2018), respectively (P<0.001). The HBsAg and HBcAb positivity rates were 2.9% and 36.5%, respectively. Antiviral prophylaxis was started in 11.8% of HBsAg-negative/HBcAb-positive patients and 40.5% of HBsAg-positive patients. HBV reactivation did not occur in patients receiving antiviral prophylaxis, but was identified in 7.2% of HBsAg-positive patients and 0.6% of HBsAg-negative/HBcAb-positive patients without antiviral prophylaxis.

Conclusion: Although HBV screening rates before chemotherapy are increasing among solid cancer patients, the rate of initiation of antiviral prophylaxis is still low. It is therefore important to raise awareness regarding HBV reactivation during/after chemotherapy.

Cite this article as: Fidan S, Fidan E, Alandağ C, Erkut M, Cosar AM. Hepatitis B virus screening and real life data in patients with solid tumor receiving chemotherapy. Arch Iran Med. 2020;23 (12):835–841. doi: 10.34172/aim.2020.111.
First Name
Last Name
Email Address
Security code

Abstract View: 1406

Your browser does not support the canvas element.

PDF Download: 685

Your browser does not support the canvas element.

Submitted: 22 Aug 2019
Revision: 24 Apr 2020
Accepted: 10 May 2020
ePublished: 01 Dec 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)